Judith M. Versluis

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al. · Nature Medicine · 2021 · 322 citations

Biomarker Analyses, Medicine, Melanoma +8

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · Nature Medicine · 2022 · 322 citations · Full text

Surgical Oncology, Oncology, Prado Trial +10

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Rebecca Simpson, Erin R. Shanahan, Marcel Batten et al. · Nature Medicine · 2022 · 216 citations

Dysbiosis, Host-microbe Interactions, Immunology +13

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials

Judith M. Versluis, Alexander M. Menzies, Karolina Sikorska et al. · Annals of Oncology · 2023 · 112 citations · Full text

Skin Cancer, Medicine, Opacin-neo Trials +7

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

Irene L. M. Reijers, Disha Rao, Judith M. Versluis et al. · The Journal of Experimental Medicine · 2023 · 70 citations · Full text

Cancer Immunosurveillance, Medicine, Donimi Trial +15